Concepedia

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments

Rehan M. Hussain, Andrea Neal, Nicolas A. Yannuzzi, Kevin H. Patel, Siya Huo, Seenu M. Hariprasad, Sumit P. Bhatia

Therapeutic Advances in Ophthalmology · 2021 · 12 citations · 14 references

DOIFull text

Open access

Abstract

In nAMD eyes previously treated with IVA and IVBe, switching to IVBr significantly reduced persistent IRF/SRF but did not significantly affect visual outcomes.

References

14

Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen

David W. M. Leung, George Cachianes, Wun-Jing Kuang et al. · Science · 1989 · 5K citations

, , +13

Prevalence of Age-Related Macular Degeneration in the United States

Archives of Ophthalmology · 2004 · 2.7K citations · Full text

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Pravin U. Dugel, Adrian Koh, Yuichiro Ogura et al. · Ophthalmology · 2019 · 871 citations · Full text

HAWK and HARRIER

Pravin U. Dugel, Rishi P. Singh, Adrian Koh et al. · Ophthalmology · 2020 · 358 citations

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen

Robyn H. Guymer, Caroline M. Markey, Ian L. McAllister et al. · Ophthalmology · 2018 · 299 citations

, , +6